Literature DB >> 7981015

Lack of pharmacokinetic interaction between vinpocetine and oxazepam.

G Storm1, B Oosterhuis, F A Sollie, H W Visscher, W Sommer, H Beitinger, J H Jonkman.   

Abstract

The influence of multiple doses of vinpocetine (10 mg three times daily) on the steady state plasma concentrations of oxazepam (10 mg three times daily) was studied in 16 healthy subjects. The mean (+/- s.d.) AUC (ng ml-1h-1) of oxazepam over 24 h during combined treatment was 4716 +/- 2296 and for oxazepam treatment alone it was 4737 +/- 2448 (95% confidence intervals for ratio of means = 95.4-103.7%). The degree of plasma protein binding of oxazepam was 98.11 +/- 0.32% and was not affected by vinpocetine. Independent of vinpocentine treatment a significant diurnal change in the plasma binding of oxazepam was observed; the free drug fraction was 20% higher during the night than during the day. Cmax and AUC values based on total oxazepam in plasma were 10% lower during the night. The results indicate a lack of influence of vinpocetine on oxazepam kinetics. Diurnal changes in the plasma binding of oxazepam probably have no clinical consequences.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7981015      PMCID: PMC1364860          DOI: 10.1111/j.1365-2125.1994.tb04338.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  16 in total

1.  Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes.

Authors:  I Hindmarch; H H Fuchs; H Erzigkeit
Journal:  Int Clin Psychopharmacol       Date:  1991       Impact factor: 1.659

2.  Vinpocetine therapy does not change imipramine pharmacokinetics in man.

Authors:  G Hitzenberger; R Schmid; W Braun; R Grandt
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1990-03

3.  A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability.

Authors:  D J Schuirmann
Journal:  J Pharmacokinet Biopharm       Date:  1987-12

4.  Delayed recovery from a sedative: correlation of the plasma levels of diazepam with clinical effects after oral and intravenous administration.

Authors:  E S Baird; D M Hailey
Journal:  Br J Anaesth       Date:  1972-08       Impact factor: 9.166

5.  Vinpocetine prevents ischemic cell damage in rat hippocampus.

Authors:  D Sauer; R Rischke; T Beck; C Rossberg; H D Mennel; G W Bielenberg; J Krieglstein
Journal:  Life Sci       Date:  1988       Impact factor: 5.037

6.  Statistical analysis of bioavailability studies: parametric and nonparametric confidence intervals.

Authors:  V W Steinijans; E Diletti
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 7.  Clinical pharmacokinetics of oxazepam and lorazepam.

Authors:  D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1981 Mar-Apr       Impact factor: 6.447

8.  A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction.

Authors:  R Balestreri; L Fontana; F Astengo
Journal:  J Am Geriatr Soc       Date:  1987-05       Impact factor: 5.562

9.  Pharmacokinetics of vinpocetine and apovincaminic acid in patients with impaired renal function.

Authors:  P Miskolczi; L Vereczkey; L Szalay; C S Göndöcs
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Apr-Jun       Impact factor: 2.441

10.  Vinpocetine increases the neuroprotective effect of adenosine in vitro.

Authors:  J Krieglstein; R Rischke
Journal:  Eur J Pharmacol       Date:  1991-11-19       Impact factor: 4.432

View more
  1 in total

1.  The Effect of Vinpocetine on Human Cytochrome P450 Isoenzymes by Using a Cocktail Method.

Authors:  Lingti Kong; Chunli Song; Linhu Ye; Daohua Guo; Meiling Yu; Rong Xing
Journal:  Evid Based Complement Alternat Med       Date:  2016-02-24       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.